AstraZeneca’s coronavirus vaccine candidate has shown 79% efficacy against symptomatic disease and 100% efficacy against severe illness and hospitalization, the drugmaker announced Monday.

In phase 3 of the company’s clinical trial, AstraZeneca said the vaccine “was well-tolerated” and that an independent safety board “identified no safety concerns.”

The vaccine, developed with Oxford University, set off alarm bells in recent weeks amid concerns that it may cause blood clotting, but the safety board found “no increased risk of thrombosis or events characterized by thrombosis” among the nearly 22,000 participants who received at least one dose of the vaccine.

AstraZeneca said it will use the data to apply to the Food and Drug Administration for emergency authorization of the vaccine in the U.S. Additionally, AstraZeneca said it will submit its discovery to a scientific journal for peer review.

WI Guest Author

This correspondent is a guest contributor to The Washington Informer.

Leave a comment

Your email address will not be published.